- Home
- GFR vs ABSI Comparison
GFR vs ABSI Comparison
Compare GFR & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- ABSI
- Stock Information
- Founded
- GFR 2018
- ABSI 2011
- Country
- GFR Canada
- ABSI United States
- Employees
- GFR N/A
- ABSI N/A
- Industry
- GFR
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- GFR
- ABSI Health Care
- Exchange
- GFR Nasdaq
- ABSI Nasdaq
- Market Cap
- GFR 318.9M
- ABSI 338.0M
- IPO Year
- GFR N/A
- ABSI 2021
- Fundamental
- Price
- GFR $5.25
- ABSI $2.39
- Analyst Decision
- GFR
- ABSI Strong Buy
- Analyst Count
- GFR 0
- ABSI 5
- Target Price
- GFR N/A
- ABSI $7.98
- AVG Volume (30 Days)
- GFR 39.2K
- ABSI 4.4M
- Earning Date
- GFR 08-06-2025
- ABSI 08-12-2025
- Dividend Yield
- GFR N/A
- ABSI N/A
- EPS Growth
- GFR N/A
- ABSI N/A
- EPS
- GFR 2.05
- ABSI N/A
- Revenue
- GFR $516,308,125.00
- ABSI $4,138,000.00
- Revenue This Year
- GFR N/A
- ABSI $44.71
- Revenue Next Year
- GFR $27.03
- ABSI $374.26
- P/E Ratio
- GFR $2.52
- ABSI N/A
- Revenue Growth
- GFR N/A
- ABSI 27.32
- 52 Week Low
- GFR $3.81
- ABSI $2.01
- 52 Week High
- GFR $8.16
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- GFR 67.48
- ABSI 33.33
- Support Level
- GFR $4.14
- ABSI $2.50
- Resistance Level
- GFR $5.01
- ABSI $2.73
- Average True Range (ATR)
- GFR 0.25
- ABSI 0.18
- MACD
- GFR 0.07
- ABSI -0.04
- Stochastic Oscillator
- GFR 97.96
- ABSI 1.94
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.